ADC Therapeutics (NYSE: ADCT) insider transactions
In the twelve months to 10 November 2026, executives and directors of ADC Therapeutics reported 6 open-market sales of 5,880,415 shares ($19.6m) and 0 open-market purchases, by 1 person, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 30 June 2026 | Mallik Ameet | Chief Executive Officer | Grant or award | +675,000 | — | 2,121,769 | Form 4 |
| 30 June 2026 | Carmona Jose | Chief Financial Officer | Grant or award | +203,700 | — | 938,076 | Form 4 |
| 30 June 2026 | Graham Peter J | Chief Legal Officer | Grant or award | +221,100 | — | 841,640 | Form 4 |
| 30 June 2026 | Zaki Mohamed | Chief Medical Officer | Grant or award | +213,900 | — | 896,317 | Form 4 |
| 3 June 2026 | Coughlin Timothy | Director | Shares withheld for tax | −12,600 | $3.08 | 72,400 | Form 4 |
| 3 June 2026 | Bizzari Jean-pierre | Director | Shares withheld for tax | −12,600 | $3.08 | 139,302 | Form 4 |
| 3 June 2026 | Hug Peter | Director | Shares withheld for tax | −2,156 | $3.08 | 263,344 | Form 4 |
| 3 June 2026 | Monges Viviane | Director | Shares withheld for tax | −2,596 | $3.08 | 186,447 | Form 4 |
| 3 June 2026 | Sandor Victor | Director | Shares withheld for tax | −12,600 | $3.08 | 140,686 | Form 4 |
| 3 June 2026 | Squarer Ron | Director | Shares withheld for tax | −15,196 | $3.08 | 123,431 | Form 4 |
| 3 June 2026 | Azelby Robert | Director | Shares withheld for tax | −12,600 | $3.08 | 112,805 | Form 4 |
| 1 June 2026 | Coughlin Timothy | Director | Grant or award | +45,000 | — | 85,000 | Form 4 |
| 1 June 2026 | Bizzari Jean-pierre | Director | Grant or award | +45,000 | — | 151,902 | Form 4 |
| 1 June 2026 | Hug Peter | Director | Grant or award | +45,000 | — | 265,500 | Form 4 |
| 1 June 2026 | Monges Viviane | Director | Grant or award | +45,000 | — | 189,043 | Form 4 |
| 1 June 2026 | Sandor Victor | Director | Grant or award | +45,000 | — | 153,286 | Form 4 |
| 1 June 2026 | Squarer Ron | Director | Grant or award | +45,000 | — | 138,627 | Form 4 |
| 1 June 2026 | Azelby Robert | Director | Grant or award | +45,000 | — | 125,405 | Form 4 |
| 2 April 2026 | RedCo II Master Fund, L.P. | — | Open-market sale | −2,634,506 | $3.28 | 12,666,731 | Form 4 |
| 2 April 2026 | RedCo II Master Fund, L.P. | — | Open-market sale | −2,529,491 | $3.28 | 10,265,297 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the ADC Therapeutics page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.